S'abonner

Intrarectal diazepam following pelvic reconstructive surgery: a double-blind, randomized placebo-controlled trial - 20/07/22

Doi : 10.1016/j.ajog.2022.05.009 
Emily R. Aldrich, MD , Tiffanie Y. Tam, MD, Leah M. Saylor, DO, Catrina C. Crisp, MSC, MD, Jennifer Yeung, DO, Rachel N. Pauls, MD
 Department of Urogynecology, TriHealth, Cincinnati, OH 

Corresponding author: Emily R. Aldrich, MD.

Abstract

Background

Patients undergoing vaginal hysterectomy with native tissue pelvic reconstruction typically have low pain levels overall in the postoperative period. Notwithstanding, pain control immediately after surgery may be more challenging and a barrier to same-day discharge. Intrarectal diazepam has been used for acute and chronic pelvic pain and has a pharmacokinetic profile ideal for intermittent use. However, its use has not been investigated after the surgical intervention.

Objective

This study aimed to evaluate the effect of diazepam rectal suppositories on early postoperative pain after hysterectomy and vaginal reconstruction for pelvic organ prolapse.

Study Design

This was a double-blind, randomized, placebo-controlled trial comparing postoperative pain scores after vaginal hysterectomy with native tissue prolapse repairs. Patients were randomized to receive either an intrarectal 10-mg diazepam suppository or an identical placebo. Moreover, the participants completed the questionnaires at baseline, the morning of postoperative day 1, and 2 weeks after the operation. Surveys included visual analog scales for pain, a validated Surgical Satisfaction Questionnaire, and queries regarding medication side effects and postoperative recovery. The primary outcome was pain scores based on a visual analog scale approximately 3 hours after surgery. The secondary outcomes included total morphine equivalents after surgery, patient satisfaction with pain control, same-day discharge outcome, and overall satisfaction. The chi-square, Fisher exact, and Mann-Whitney tests were used. Based on a 10-mm difference in postoperative vaginal pain using the visual analog scale, sample size was calculated to be 55 patients in each arm to achieve 80% power with an alpha of.05.

Results

From February 2020 to August 2021, 130 participants were randomized. Of those participants, 7 withdrew, and 123 were analyzed: 60 in the diazepam group and 63 in the placebo group. The median age was 65 years (interquartile range, 27–80), the median body mass index was 27.9 kg/m2 (interquartile range, 18.70–45.90), and 119 of 123 participants (96.7%) were White. There was no difference in the baseline characteristics, prolapse stage, or types of procedures performed between groups. Most participants had concurrent uterosacral ligament suspension with anterior and posterior repairs. Of note, 50 of 123 participants (41%) had midurethral slings. Moreover, 61 of 123 participants (50%) were discharged on the day of surgery. There was no difference in the primary outcome of vaginal pain 3.5 to 6.0 hours postoperatively (25 vs 21 mm; P=.285). In addition, the amount of rescue narcotics used in the immediate postoperative period (19.0 vs 17.0 MME; P=.202) did not differ between groups. At 2-weeks postoperatively, patients in the placebo group reported higher satisfaction with pain control in the hospital (31 vs 43 mm; P=.006) and pain control at home (31 vs 42 mm; P=.022). No difference was noted between same-day discharges and those who were admitted overnight.

Conclusion

The placement of a 10-mg diazepam rectal suppository immediately after pelvic reconstructive surgery did not improve pain or narcotic usage in the early postoperative period. Although the placebo group reported slightly higher satisfaction with pain control 2 weeks after surgery, overall pain levels were low. Therefore, we do not believe that the addition of diazepam to the postoperative regimen is warranted.

Le texte complet de cet article est disponible en PDF.

Key words : diazepam, hysterectomy, intrarectal diazepam, pain, pelvic reconstructive surgery, postoperative pain, prolapse, suppository, vaginal hysterectomy


Plan


 The authors report no conflict of interest.
 This study received funding from the TriHealth Medical Education Research Fund. The funding source had no role in the development, data collection or analysis, or writing of this report.
 This study was registered on ClinicalTrials.gov (identification number: NCT04198233; NCT04198233). The clinical trial date of registration was on December 13, 2019. The date of initial participant enrollment was on February 12, 2020.
 Individual participant data will be available. All enrollment and collected data will be shared. Study protocol, informed consent document, data collection forms will be available. Data will be available on study publication. Data will be shared via secured messaging system with interested parties for secondary analyses.
 Cite this article as: Aldrich ER, Tam TY, Saylor LM, et al. Intrarectal diazepam following pelvic reconstructive surgery: a double-blind, randomized placebo-controlled trial. Am J Obstet Gynecol 2022;227:302.e1-9.


© 2022  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 227 - N° 2

P. 302.e1-302.e9 - août 2022 Retour au numéro
Article précédent Article précédent
  • Altmetric and bibliometric analysis of obstetrics and gynecology research: influence of public engagement on citation potential
  • Sonal Grover, Adam D. Elwood, Jharna M. Patel, Cande V. Ananth, Justin S. Brandt
| Article suivant Article suivant
  • Development and validation of a simulation model for laparoscopic myomectomy
  • Rebecca J. Schneyer, Andrea L. Molina, Isabel C. Green, Stacey A. Scheib, Kristin C. Mara, Matthew T. Siedhoff, Kelly N. Wright, Mireille D. Truong

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.